Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study

Annals of the Rheumatic Diseases

Volumn 76, Issue 2, 2017, Pages 346-354

  Park, Won ^a   Yoo, Dae Hyun ^b   Miranda, Pedro ^c   Brzosko, Marek ^d   Wiland, Piotr ^e   Gutierrez Ureña, Sergio ^f   Mikazane, Helena ^g   Lee, Yeon Ah ^h   Smiyan, Svitlana ⁱ   Lim, Mie Jin ^a   Kadinov, Vladimir ^j   Abud Mendoza, Carlos ^k   Kim, Houng ^l   Lee, Sang Joon ^l   Bae, Yunju ^l   Kim, Suyeon ^l   Braun, Jürgen ^m  

^a Inha University School of Medicine   (South Korea)

^b Hanyang University Hospital for Rheumatic Diseases   (South Korea)

^c UNIVERSITY OF CHILE   (Chile)

^d POMERANIAN MEDICAL UNIVERSITY   (Poland)

^e WROCLAW MEDICAL UNIVERSITY   (Poland)

^f UNIVERSITY OF GUADALAJARA   (Mexico)

^g Outpatient Clinic ORTO   (Latvia)

^h Kyung Hee University   (South Korea)

ⁱ I HORBACHEVSKY TERNOPIL NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^j UNIVERSITY HOSPITAL ST MARINA   (Bulgaria)

^k UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^l Celltrion Inc   (South Korea)

^m RHEUMAZENTRUM RUHRGEBIET   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; CREATINE KINASE; CT P 13; DRUG ANTIBODY; INFLIXIMAB; UNCLASSIFIED DRUG; ANTIBODY; ANTIRHEUMATIC AGENT; CT-P13; MONOCLONAL ANTIBODY;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ARTICLE; BACKACHE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HEADACHE; HERPES VIRUS INFECTION; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; IMMUNOGENICITY; INFECTION; INFUSION RELATED REACTION; LATENT TUBERCULOSIS; LEUKOPENIA; LIVER DISEASE; LOWER RESPIRATORY TRACT INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; SIDE EFFECT; SINUSITIS; TOXIC HEPATITIS; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VASCULAR DISEASE; WEIGHT GAIN; WEIGHT REDUCTION; ADOLESCENT; CLINICAL TRIAL; DRUG RESISTANCE; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOSIMILAR PHARMACEUTICALS; DRUG RESISTANCE; DRUG SUBSTITUTION; FEMALE; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84965014483     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208783     Document Type: Article

References (32)

1. WHO, World Health Organization. Expert Committee on Biological Standardization. Geneva, 19 to 23 October 2009. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009. http://www.who.int/biologicals/areas/biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf (accessed 19 Feb 2015).
2. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on Similar Biological Medicine Products (CHMP/437/04 Rev 1).
3. October 2014. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/10/WC500176768.pdf (accessed 2 Jul 2015).
4. U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Guidance for Industry. April 2015. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf (accessed 2 Jul 2015).
5. Feagan BG, Choquette D, Ghosh S, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals 2014;42:177-83.
6. Jung SK, Lee KH, Jeon JW, et al. Physicochemical characterization of Remsima. MAbs 2014;6:1163-77.
7. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013;72:1605-12.
8. Park W, Yoo DH, Jaworski J, et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther 2016;18:25.
9. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013;72:1613-20.
10. Yoo DH, Racewicz A, Brzezicki J, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther 2016;18:82.
11. Ebbers HC, Crow SA, Vulto AG, et al. Interchangeability, immunogenicity and biosimilars. Nat Biotechnol 2012;30:1186-90.
12. Tóthfalusi L, Endrényi L, Chow SC. Statistical and regulatory considerations in assessments of interchangeability of biological drug products. Eur J Health Econ 2014;15(Suppl.1):S5-11.
13. Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis 2017;76:355-63.
14. Braun J, Brandt J, Listing J, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003;48:2224-33.
15. Van Der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
16. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
17. Braun J, Deodhar A, Dijkmans B, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum 2008;59:1270-8.
18. Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65.
19. Braun J, Brandt J, Listing J, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005;64:229-34.
20. Breban M, Ravaud P, Claudepierre P, et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 2008;58:88-97.
21. Inman RD, Maksymowych WP, Group CS. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol 2010;37:1203-10.
22. Temekonidis TI, Alamanos Y, Nikas SN, et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 2003;62:1218-20.
23. Gossec L, Le Henanff A, Breban M, et al. Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up. Rheumatology (Oxford) 2006;45:859-62.
24. Plasencia C, Pascual-Salcedo D, Nuño L, et al. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. Ann Rheum Dis 2012;71:1955-60.
25. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
26. Davis-Ajami ML, Wu J, Downton K, et al. Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility. Biologics 2014;8:155-67.
27. Flodmark CE, Lilja K, Woehling H, et al. Switching from originator to biosimilar human growth hormone using dialogue teamwork: single-center experience from Sweden. Biol Ther 2013;3:35-43.
28. Haag-Weber M, Vetter A, Thyroff-Friesinger U, et al. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol 2009;72:380-90.
29. Lubenau H, Bias P, Maly AK, et al. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial. BioDrugs 2009;23:43-51.
30. Verpoort K, Möhler TM. A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre. Ther Adv Med Oncol 2012;4:289-93.
31. Wiecek A, Ahmed I, Scigalla P, et al. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis. Adv Ther 2010;27:941-52.
32. Wizemann V, Rutkowski B, Baldamus C, et al. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin 2008;24:625-37.